Literature DB >> 32219208

Structural Characterization of Agonist Binding to Protease-Activated Receptor 2 through Mutagenesis and Computational Modeling.

Amanda J Kennedy1, Flavio Ballante2, Johan R Johansson1, Graeme Milligan3, Linda Sundström1, Anneli Nordqvist1, Jens Carlsson2.   

Abstract

Protease-activated receptor 2 (PAR2) is a G-protein-coupled receptor that is activated by proteolytic cleavage of its N-terminus. The unmasked N-terminal peptide then binds to the transmembrane bundle, leading to activation of intracellular signaling pathways associated with inflammation and cancer. Recently determined crystal structures have revealed binding sites of PAR2 antagonists, but the binding mode of the peptide agonist remains unknown. In order to generate a model of PAR2 in complex with peptide SLIGKV, corresponding to the trypsin-exposed tethered ligand, the orthosteric binding site was probed by iterative combinations of receptor mutagenesis, agonist ligand modifications, and data-driven structural modeling. Flexible-receptor docking identified a conserved binding mode for agonists related to the endogenous ligand that was consistent with the experimental data and allowed synthesis of a novel peptide (1-benzyl-1H[1,2,3]triazole-4-yl-LIGKV) with functional potency higher than that of SLIGKV. The final model may be used to understand the structural basis of PAR2 activation and in virtual screens to identify novel agonists and competitive antagonists. The combined experimental and computational approach to characterize agonist binding to PAR2 can be extended to study the many other G protein-coupled receptors that recognize peptides or proteins.
Copyright © 2018 American Chemical Society.

Entities:  

Year:  2018        PMID: 32219208      PMCID: PMC7088944          DOI: 10.1021/acsptsci.8b00019

Source DB:  PubMed          Journal:  ACS Pharmacol Transl Sci        ISSN: 2575-9108


  6 in total

1.  Discovery of Novel Nonpeptidic PAR2 Ligands.

Authors:  Ilona Klösel; Maximilian F Schmidt; Jonas Kaindl; Harald Hübner; Dorothee Weikert; Peter Gmeiner
Journal:  ACS Med Chem Lett       Date:  2020-05-22       Impact factor: 4.345

Review 2.  The domino effect triggered by the tethered ligand of the protease activated receptors.

Authors:  Xu Han; Marvin T Nieman
Journal:  Thromb Res       Date:  2020-08-04       Impact factor: 3.944

3.  Synthesis and initial pharmacology of dual-targeting ligands for putative complexes of integrin αVβ3 and PAR2.

Authors:  Mark W Majewski; Disha M Gandhi; Trudy Holyst; Zhengli Wang; Irene Hernandez; Ricardo Rosas; Jieqing Zhu; Hartmut Weiler; Chris Dockendorff
Journal:  RSC Med Chem       Date:  2020-07-09

4.  Protease-activated receptor-2 ligands reveal orthosteric and allosteric mechanisms of receptor inhibition.

Authors:  Amanda J Kennedy; Linda Sundström; Stefan Geschwindner; Eunice K Y Poon; Yuhong Jiang; Rongfeng Chen; Rob Cooke; Shawn Johnstone; Andrew Madin; Junxian Lim; Qingqi Liu; Rink-Jan Lohman; Anneli Nordqvist; Maria Fridén-Saxin; Wenzhen Yang; Dean G Brown; David P Fairlie; Niek Dekker
Journal:  Commun Biol       Date:  2020-12-17

5.  Protease-activated receptor 2 activation induces behavioural changes associated with depression-like behaviour through microglial-independent modulation of inflammatory cytokines.

Authors:  Serge Moudio; Ashleigh Willis; Karolina Pytka; Roua Abulkassim; Ros R Brett; Jack F Webster; Christian Wozny; Mark Barbour; Hui-Rong Jiang; David G Watson; Josie C van Kralingen; Scott M MacKenzie; Michael Daniels; Barry W McColl; Sandra Sossick; Hugh N Nuthall; Trevor J Bushell
Journal:  Psychopharmacology (Berl)       Date:  2021-12-09       Impact factor: 4.530

6.  The PAR2 inhibitor I-287 selectively targets Gαq and Gα12/13 signaling and has anti-inflammatory effects.

Authors:  Charlotte Avet; Claudio Sturino; Sébastien Grastilleur; Christian Le Gouill; Meriem Semache; Florence Gross; Louis Gendron; Youssef Bennani; Joseph A Mancini; Camil E Sayegh; Michel Bouvier
Journal:  Commun Biol       Date:  2020-11-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.